Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
Want to see RIGL full AI Analyst Report?
RIGL Stock Chart & Stats
$32.43
-$0.99(-5.79%)
At close: 4:00 PM EST
$32.43
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$18.14 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)400.70K
Market Cap
$607.79M
Enterprise Value$585.44M
Total Cash (Recent Filing)$146.68M
Total Debt (Recent Filing)$45.72M
Price to Earnings (P/E)1.7
Beta1.97
Next Earnings
Aug 04, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.07
Shares Outstanding18,502,080
10 Day Avg. Volume315,546
30 Day Avg. Volume400,696
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda4.46
Forecast
1Y Price Target
$59.33Price Target Upside82.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3.99
Revenue Forecast (FY)$282.83M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability TurnaroundA multi-hundred percent TTM revenue gain alongside a rapid swing to strong operating and net margins indicates the company has moved from development losses to a commercial-stage, cash-generating model. Durable revenue scale and higher margins support reinvestment, debt reduction, and strategic M&A over the next 2–6 months.
Improved Cash Generation And Positive FCFPositive and growing operating and free cash flow materially reduce financing risk and give management flexibility to fund R&D, pay down debt, and pursue business development. While cash flow still trails net income, the structural shift to sustained positive FCF is central to durable financial resilience.
Strategic Oncology Expansion Via VEPPANU DealAcquiring global rights to a targeted breast cancer therapy materially broadens the pipeline and diversifies commercial risk beyond current hematology and targeted oncology products. The deal adds milestone and royalty upside and leverages Rigel's commercial infrastructure, supporting durable revenue diversification over coming years.
Bears Say
Earnings And Cash Durability ConcernsRapid swings from losses to outsized profits suggest earnings quality and predictability remain uncertain. If non‑cash items or timing effects persist, future profitability and FCF could prove uneven, complicating planning, capital allocation, and confidence in sustaining current margins beyond near-term product tailwinds.
Termination Of Lilly CollaborationLosing a major partner removes external development funding, clinical expertise, and milestone upside for the RIPK1 program. Rigel assumes greater development and commercialization costs or must out-license the program, increasing capital needs and program-level timeline and success risk over the medium term.
Rising Operating Costs Pressuring Profits And CashOperating expenses and R&D investments rose materially, reducing quarterly net income and causing modest cash decline. If expense growth outpaces sustainable product revenue gains, margin expansion and free cash flow could reverse, forcing tradeoffs between growth investments and balance sheet preservation.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $18.14 and its highest was $52.24 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $607.79M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 49 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on May 05, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.795 by -$0.355.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 18,502,080 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $0.44 in its last earnings report, missing expectations of $0.795. Following the earnings report the stock price went down -5.055%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.33 (82.96% Upside)
$59.33 (82.96% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.22%
12-Months-Change
Fundamentals
Return on Equity
147.03%
Trailing 12-Months
Asset Growth
186.75%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering and developing small molecule therapies. The firm's focus areas include hematologic disorders, oncology, and rare immune system conditions. Its commercialized product, Tavalisse (fostamatinib), is an oral spleen tyrosine kinase inhibitor approved for the treatment of chronic immune thrombocytopenia in adult patients. Rigel's robust pipeline features Fostamatinib, currently in Phase III clinical trials for several additional indications, including warm autoimmune hemolytic anemia, as well as separate studies for hospitalized COVID-19 patients and other COVID-19 applications. In its earlier development stages, the company is advancing R289, an oral interleukin receptor associated kinase 1/4 inhibitor undergoing Phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases. Another promising compound, R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, has successfully completed Phase I clinical evaluation for autoimmune and inflammatory conditions. Rigel maintains several strategic collaborations to further its development efforts. These include research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a partnership with BerGenBio AS focusing on AXL inhibitors in oncology; and an agreement with Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies. The company also has a licensing and supply agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of Fostamatinib. Furthermore, Rigel has a significant collaboration and license agreement with Eli Lilly and Company to jointly develop and commercialize R552 for diverse therapeutic applications, including autoimmune and inflammatory disorders, alongside other non-central nervous system conditions. Founded in 1996, Rigel Pharmaceuticals, Inc. is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$59.33
▲(82.96% Upside)
Technical Analysis
Ownership Overview
3.25% Insiders
28.85% Mutual Funds
17.75% Other Institutional Investors
26.70% Public Companies and Individual Investors